Bioprocessing Cell Culture Media
For decades, biopharmaceutical companies have trusted us to deliver high performing, high quality, cell culture media (CCM) for a diverse range of biologics. Whether you need to intensify a CHO-based process or optimize production of vaccines or novel modalities such as cell and gene therapies, our cell culture media will help make your processes more robust and efficient.
What Sets Our Media Apart?
- With our comprehensive portfolio, you can choose from tried-and-true formulations or explore innovative new options that enable process intensification for monoclonal antibodies and emerging, novel modalities such as cell and gene therapies.
- We understand how media can influence the efficiency of other bioprocessing steps. Because of this, we incorporate science-driven technology into our formulations to support cell culture productivity and simplify upstream workflows.
- We back our products with a commitment to business continuity and a best-in-class application support team with a record of success with a diverse set of cell types, biologics, metabolic needs, and process requirements.
Products
Related Product Resources
White Papers
White Paper: Improving fed-batch Yields by Combining EX-CELL® Advanced and Cellvento® Cell culture Media Portfolios
White Paper: Seed Train Intensification
White Paper: Accelerating Cell Line and Process Development
White Paper: Strategies for Upstream Intensification
White Paper: Optimizing Media Feeding Strategies Guidance for Cellvento® CHO Media Platform (1st GEN)
White Paper: Use of a Chemically Defined Cloning Medium for Quality and Regulatory Risk Mitigation in Cell Line Development
We offer a broad portfolio of industry-proven CHO media for the seed train (N-1), perfusion, fed-batch, and cell line development. These purpose-built formulations are designed to contain only those raw materials that have a specific role in supporting cell vitality and productivity. As problem solvers we also identify opportunities to further improve media consistency and handling, such as modified amino acids, a novel poloxamer, auto pH, and compaction to match novel process designs.
The result? Media that are tailored for your specific CHO-based application, maximizing productivity and enabling upstream process intensification – while keeping pace with evolving regulatory requirements.
For fed-batch processes, we aim to reduce the complexity of workflows by offering highly concentrated, one-part pH neutral feeds, allowing for a reduction in volume of feed added to replenish depleted nutrients, thereby increasing product yield. Highly concentrated, compacted format, easy to hydrate and product stability even at room temperature allow for streamlined workflows.
INSECT MEDIA FOR PRODUCTION OF VACCINE AND GENE THERAPY
The insect cell expression system has become an established manufacturing platform to produce recombinant proteins, virus-like particles (VLP) for vaccines, and adeno-associated viruses (AAV) to treat genetic diseases. The production of vaccine and gene therapy with insect cells requires specialized media that deliver high performance and high quality. Our media is chemically defined and specifically formulated to support robust growth of multiple insect cell lines, such as Sf-RVN®, Sf-9, Sf-21, S2, Tni and C636. The Insect CD media promotes excellent productivity and high-quality titers.
HEK293 MEDIA FOR PRODUCTION OF GENE THERAPY
The human cell line HEK293 is commonly used in the production of viral vectors for gene therapy and gene-modified cell therapy. Our HEK293 media for AAV and Lentivirus production incorporate carefully selected, high-quality raw materials and supplements for optimal cell expansion, transient transfection, and for producing high titer viral vectors. The media is chemically defined, animal component free, and specifically formulated to promote excellent growth and productivity of HEK cell lines. The media support suspension cell culture and are amendable to multiple types of transfection reagents such as PEI and other cationic polymers.
Highlights
To continue reading please sign in or create an account.
Don't Have An Account?